A citation-based method for searching scientific literature


List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
50

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
50

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
422
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
444
33

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
344
33

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Jan H Cornel, George L Bakris, Susanna R Stevens, Michael Alvarsson, Willem A Bax, Lee-Ming Chuang, Samuel S Engel, Renato D Lopes, Darren K McGuire, Axel Riefflin,[...]. Diabetes Care 2016
80
33

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Darren K McGuire, Frans Van de Werf, Paul W Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B Green, M Angelyn Bethel, Jan H Cornel, Renato D Lopes, Sigrun Halvorsen,[...]. JAMA Cardiol 2016
133
33

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Richard E Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B Huyck, Yanping Qiu, Sheila Sunga, Jeremy Johnson, Steven G Terra, James P Mancuso,[...]. Diabetes Obes Metab 2018
72
33

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Baptist Gallwitz, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, Klaus A Dugi, Hans-Juergen Woerle. Lancet 2012
242
33

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Yehuda Handelsman, Chantal Mathieu, Stefano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez, Julio Rosenstock. Diabetes Obes Metab 2019
10
33




A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
183
33

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
317
33



Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
290
33

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
M B Rehman, B V Tudrej, J Soustre, M Buisson, P Archambault, D Pouchain, H Vaillant-Roussel, F Gueyffier, J-L Faillie, M-C Perault-Pochat,[...]. Diabetes Metab 2017
55
33


2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
189
33

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
220
33

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
753
33

Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course.
Amy G Huebschmann, Rachel R Huxley, Wendy M Kohrt, Philip Zeitler, Judith G Regensteiner, Jane E B Reusch. Diabetologia 2019
30
33

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey.
Björn Eliasson, Jan Ekelund, Rikard Amberntsson, Mervete Miftaraj, Ann-Marie Svensson. Diabetes Ther 2019
2
100

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
539
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
16

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
Caroline S Fox, Kunihiro Matsushita, Mark Woodward, Henk J G Bilo, John Chalmers, Hiddo J Lambers Heerspink, Brian J Lee, Robert M Perkins, Peter Rossing, Toshimi Sairenchi,[...]. Lancet 2012
510
16

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Samuel S Engel, Shailaja Suryawanshi, Susanna R Stevens, Robert G Josse, Jan H Cornel, Neli Jakuboniene, Axel Riefflin, Tsvetalina Tankova, Julio Wainstein, Eric D Peterson,[...]. Diabetes Obes Metab 2017
14
16

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Darren K McGuire, John H Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E Cooper, Christoph Wanner, Steven E Kahn, Robert D Toto, Bernard Zinman,[...]. Circulation 2019
71
16

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Ron T Gansevoort, Ricardo Correa-Rotter, Brenda R Hemmelgarn, Tazeen H Jafar, Hiddo J Lambers Heerspink, Johannes F Mann, Kunihiro Matsushita, Chi Pang Wen. Lancet 2013
784
16


Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
A J Scheen. Diabetes Obes Metab 2010
176
16

Excess Mortality among Persons with Type 2 Diabetes.
Mauro Tancredi, Annika Rosengren, Ann-Marie Svensson, Mikhail Kosiborod, Aldina Pivodic, Soffia Gudbjörnsdottir, Hans Wedel, Mark Clements, Sofia Dahlqvist, Marcus Lind. N Engl J Med 2015
416
16

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
180
16

The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Angelo Avogaro, Gian Paolo Fadini. Br J Clin Pharmacol 2018
11
16

Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
C Mathieu, M Herrera Marmolejo, J G González González, L Hansen, H Chen, E Johnsson, R Garcia-Sanchez, N Iqbal. Diabetes Obes Metab 2016
37
16

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka,[...]. Cardiovasc Diabetol 2017
7
16

Diabetes: Assessing renal risk in patients with type 2 diabetes.
Merlin C Thomas, Per-Henrik Groop. Nat Rev Nephrol 2013
4
25

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
334
16

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
191
16


Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Roberto Pecoits-Filho, Vlado Perkovic. Clin J Am Soc Nephrol 2018
22
16

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Ofri Mosenzon, Gil Leibowitz, Deepak L Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre,[...]. Diabetes Care 2017
112
16

One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
S Matthaei, N Aggarwal, P Garcia-Hernandez, N Iqbal, H Chen, E Johnsson, A Chin, L Hansen. Diabetes Obes Metab 2016
26
16

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, Itamar Raz, Bryan Goldman, Thomas Idorn, Bernt Johan von Scholten, Neil R Poulter. Circulation 2018
29
16

Chronic kidney disease.
Paola Romagnani, Giuseppe Remuzzi, Richard Glassock, Adeera Levin, Kitty J Jager, Marcello Tonelli, Ziad Massy, Christoph Wanner, Hans-Joachim Anders. Nat Rev Dis Primers 2017
135
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.